Thermo Fisher Scientific to Source Half of its U.S. Electricity Needs from Wind Power Purchase with Enel North America

The agreement will deliver renewable energy equal to half of the company's U.S. electricity consumption

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, recently signed an eight-year virtual power purchasing agreement with Enel North America to deliver a 90-megawatt (MW) portion of the Seven Cowboy wind project in western Oklahoma. Thermo Fisher will purchase approximately 400,000 megawatt hours (MWh) of renewable electricity, equal to half of the company's current U.S. electricity needs.

As part of the company's emissions-reduction strategy, Thermo Fisher plans to eventually transition most locations globally to renewable energy. Today, more than 60 sites worldwide are fully powered by renewable electricity, including seven facilities that generate 3.5 MW of solar power and 3 MW of wind energy. Another 15 MW of solar power projects are planned.

"By sourcing electricity from new wind and solar facilities we can help our customers meet their Scope 3 greenhouse gas reduction targets," said Konrad Bauer, senior vice president, global business services, Thermo Fisher Scientific. "This project will more than double our use of renewable energy and, combined with our $20 million investment in green infrastructure earlier this year, supports our commitment to a net-zero value chain by 2050."

The Seven Cowboy Wind project is expected to be operational by the second half of 2023. Schneider Electric advised Thermo Fisher on this agreement. Additional information about Thermo Fisher's environmental, social, and governance progress can be found at www.thermofisher.com/csr .

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com .

Media Relations
Sandy Pound
Phone: 781-622-1223
Email: sandy.pound@thermofisher.com

Investor
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

News Provided by Business Wire via QuoteMedia

TMO
The Conversation (0)
Seegnal (TSXV:SEGN)

Seegnal Presents Real-World Evidence on Reducing Fall Risk in Geriatric Patients at Caltcm Summit

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in AI-enhanced prescription intelligence, today announced real-world clinical results demonstrating how medication governance may reduce fall-risk drivers in older adults -- a significant clinical and financial challenge... Keep Reading...
Cardiologist wearing virtual reality glasses.

Top 3 Medical Device ETFs for Investors in 2026

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or... Keep Reading...
Stethoscope connected to a phone with medical data overlay.

Top 3 Small-cap Medical Device Stocks (Updated January 2026)

The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug Administration (FDA).Wearable medical devices and the use of artificial intelligence in medical... Keep Reading...
Scientists working in a modern medical research laboratory.

Pathways to Commercialising Biotech Innovations

In the medical technology industry, innovation is only the first step. While key to long-term success, innovation is only as good as a company’s commercialisation strategy. Once a technology has been developed and proven, the organisation must then embark on a process to commercialise it for... Keep Reading...
Medical devices on a desk.

How to Invest in Medical Device Stocks and ETFs

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and... Keep Reading...
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians. BlinkLab states in its Wednesday (March 12) release that the study is the largest digital... Keep Reading...

Interactive Chart

Latest Press Releases

Related News